A randomized controlled study to evaluate the safety and feasibility of concomitant transluminal injection of foam sclerosant combined with endovenous laser ablation in patients with incompetent small saphenous veins.

Phlebology Pub Date : 2025-03-01 Epub Date: 2024-08-29 DOI:10.1177/02683555241276709

Satoshi Watanabe, Atsunori Okamura, Mutsumi Iwamoto, Akinori Sumiyoshi, Kota Tanaka, Heitaro Watanabe, Yoshitaka Iwanaga, Katsuomi Iwakura

{"title":"A randomized controlled study to evaluate the safety and feasibility of concomitant transluminal injection of foam sclerosant combined with endovenous laser ablation in patients with incompetent small saphenous veins.","authors":"Satoshi Watanabe, Atsunori Okamura, Mutsumi Iwamoto, Akinori Sumiyoshi, Kota Tanaka, Heitaro Watanabe, Yoshitaka Iwanaga, Katsuomi Iwakura","doi":"10.1177/02683555241276709","DOIUrl":null,"url":null,"abstract":"Objectives: To compare foam sclerotherapy through the access sheath (transluminal foam sclerotherapy [TLFS]) combined with endovenous laser ablation (EVLA) with EVLA alone in terms of safety and one-year venous clinical severity score (VCSS) changes in patients with small saphenous vein incompetence.Methods: During EVLA, the sheath tip was placed around the targeted tributary vein, and the sclerosant was injected via the side port. Outcomes assessed at 1 day, 1 week, 1 month, and 1 year included VCSS changes, residual or recurrent reflux, the need for secondary interventions, and other related complications.Results: The change in VCSS did not reach the minimum clinically important difference. Otherwise, TLFS reduced residual or recurrent reflux of the tributary using the TLFS (3/74 legs) compared with the EVLA alone (12/77 legs) (p = .027).Conclusions: TLFS is a safe and feasible procedure that reduces residual or recurrent reflux of the tributary vein compared with truncal EVLA alone.","PeriodicalId":94350,"journal":{"name":"Phlebology","volume":" ","pages":"116-125"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02683555241276709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To compare foam sclerotherapy through the access sheath (transluminal foam sclerotherapy [TLFS]) combined with endovenous laser ablation (EVLA) with EVLA alone in terms of safety and one-year venous clinical severity score (VCSS) changes in patients with small saphenous vein incompetence.

Methods: During EVLA, the sheath tip was placed around the targeted tributary vein, and the sclerosant was injected via the side port. Outcomes assessed at 1 day, 1 week, 1 month, and 1 year included VCSS changes, residual or recurrent reflux, the need for secondary interventions, and other related complications.

Results: The change in VCSS did not reach the minimum clinically important difference. Otherwise, TLFS reduced residual or recurrent reflux of the tributary using the TLFS (3/74 legs) compared with the EVLA alone (12/77 legs) (p = .027).

Conclusions: TLFS is a safe and feasible procedure that reduces residual or recurrent reflux of the tributary vein compared with truncal EVLA alone.

查看原文本刊更多论文

一项随机对照研究，旨在评估小隐静脉闭塞患者同时进行腔内注射泡沫硬化剂和静脉腔内激光消融术的安全性和可行性。

目的比较通过入路鞘进行泡沫硬化剂治疗（腔内泡沫硬化剂治疗[TLFS]）联合静脉腔内激光消融术（EVLA）与单独使用EVLA在安全性和一年静脉临床严重程度评分（VCSS）变化方面的效果：EVLA过程中，将鞘尖置于目标支静脉周围，通过侧孔注入硬化剂。1天、1周、1个月和1年后的评估结果包括VCSS变化、残留或复发反流、二次干预的需要以及其他相关并发症：结果：VCSS 的变化未达到最小临床重要差异。此外，与单独使用 EVLA（12/77 条腿）相比，使用 TLFS 减少了支流残留或复发性反流（3/74 条腿）（p = .027）：结论：TLFS是一种安全可行的手术，与单纯截肢EVLA相比，TLFS可减少支静脉的残留或复发性反流。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phlebology

自引率

0.00%

发文量